| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439357 | European Journal of Cancer | 2018 | 12 Pages |
Abstract
These results indicate that dasatinib enhances the antitumour activity of MEK inhibitor through inhibition of TAZ activity and identify dasatinib and trametinib combination as a potential strategy for the treatment of KRAS-driven cancers.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Guanhua Rao, In-kyu Kim, Fabio Conforti, Jing Liu, Yu-Wen Zhang, Giuseppe Giaccone,